TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8207740

Group type: EXPERIMENTAL
Intervention: cilazapril (2.5 mg daily)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: nifedipine retard (20 mg twice daily)
Number of subjects: 31
Study: 2913579

Group type: EXPERIMENTAL
Intervention: 1:1 (2 msec on, 2 msec off) pulsed‐output ultrasound (3.0 MHz at 1.0 W/cm2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous‐output ultrasound at 0.75, 1.5, and 3.0 MHz at 1.5 W/cm2
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (0.0 W/cm2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo control (benzydamine gel massaged with ultrasound applicator switched off)
Number of subjects: 10
Study: 31558454

Group type: EXPERIMENTAL
Intervention: Individual-level questions about latrine use or open defecation for every household member
Number of subjects: 2431

Group type: COMPARATOR
Intervention: Household-level question used in India's DHS
Number of subjects: 2431

Group type: EXPERIMENTAL
Intervention: Individual-level questions among households that received assistance to construct their latrines
Number of subjects: 2431

Group type: COMPARATOR
Intervention: Household-level question among households that received assistance to construct their latrines
Number of subjects: 2431
Study: 29066147

Group type: EXPERIMENTAL
Intervention: 30 mg/kg of methylprednisolone intravenously after anesthesia induction (n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 30 mg/kg of methylprednisolone in cardiopulmonary bypass prime solution (n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 45
Study: 25515800

Group type: EXPERIMENTAL
Intervention: Coping strategies intervention (series of five interventions every 2 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual clinical management (control group, telephoned every 2 weeks)
Number of subjects: 57
Study: 24372225

Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks (Q2W)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: CZP 400 mg every 4 weeks
Number of subjects: 98
Study: 23017533

Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Clinic-based intervention (CBI)
Number of subjects: 280
Study: 18706557

Group type: EXPERIMENTAL
Intervention: Low-dose oral hormone therapy (E(2) 1 mg plus drospirenone 2 mg/d for 2 months)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nonoral hormone therapy (3 mg/d 17beta intranasal E(2) and 200 mg/d vaginal micronized P for 14 days during two 28-day cycles)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 17127043

Group type: EXPERIMENTAL
Intervention: Fish oil (n-3 fatty acids 3.6 g/day)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 16102378

Group type: EXPERIMENTAL
Intervention: Brief intervention with a consistent support person
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both intervention and usual care groups
Number of subjects: 127
Study: 11984296

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham‐training control (placebo)
Number of subjects: 16
Study: 9859904

Group type: EXPERIMENTAL
Intervention: Nebulizer (2 mg/dose in 2.8 mL of 0.9% saline solution)
Number of subjects: 34

Group type: COMPARATOR
Intervention: MDI-spacer (0.5 mg/dose)
Number of subjects: 34
Study: 8567554

Group type: EXPERIMENTAL
Intervention: Normoxia (inspired O2 fraction = 0.21)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hypoxia (inspired O2 fraction = 0.14)
Number of subjects: 9
Study: 2225478

Group type: EXPERIMENTAL
Intervention: Amiodarone plus propylthiouracil (PTU, 100 mg orally every 8 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propylthiouracil (PTU) alone
Number of subjects: 0
Study: 472913

Group type: EXPERIMENTAL
Intervention: Oral PGE2 (5 mg total dose)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intravaginal PGE2 (4-6 mg in gel form)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (unsuitable for induction)
Number of subjects: 33
Study: 31232891

Group type: EXPERIMENTAL
Intervention: Short cephalomedullary nail (SN)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Long cephalomedullary nail (LN)
Number of subjects: 220
Study: 28575048

Group type: EXPERIMENTAL
Intervention: Weight management program delivered via Facebook group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight management program delivered via pamphlet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 0
Study: 25434288

Group type: EXPERIMENTAL
Intervention: CAD-CAM technology with surgical cutting guides and customised bone plates
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not treated with CAD-CAM technology)
Number of subjects: 10
Study: 22621941

Group type: EXPERIMENTAL
Intervention: Active t-VNS (stimulation)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham t-VNS (no stimulation)
Number of subjects: 48
Study: 21613038

Group type: EXPERIMENTAL
Intervention: Single-bottle adhesives with delayed composite placement
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Double application of single-bottle adhesives with delayed composite placement
Number of subjects: 140

Group type: COMPARATOR
Intervention: Single application of single-bottle adhesives with immediate composite placement
Number of subjects: 140
Study: 19336505

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (postmenopausal women without PHPT)
Number of subjects: 39
Study: 16461091

Group type: COMPARATOR
Intervention: Placebo for 2 months (Group 1)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil 45 minutes before coitus for 2 months (Group 2)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil 45 minutes before coitus plus topical EMLA cream applied 15 minutes before coitus for 2 months (Group 3)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Topical EMLA-cream-only for 2 months (Group 4)
Number of subjects: 84
Study: 15306156

Group type: EXPERIMENTAL
Intervention: T/T genotype
Number of subjects: 159

Group type: COMPARATOR
Intervention: C/C and C/T genotypes
Number of subjects: 159
Study: 10072214

Group type: COMPARATOR
Intervention: Conventional balloon PTCA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Perfusion balloon PTCA
Number of subjects: 48
Study: 8650033

Group type: EXPERIMENTAL
Intervention: Mini Mental State
Number of subjects: 335

Group type: COMPARATOR
Intervention: DSWM III R criteria for dementing syndromes
Number of subjects: 335
Study: 2370507

Group type: EXPERIMENTAL
Intervention: Diet history interview
Number of subjects: 80

Group type: COMPARATOR
Intervention: Self completed questionnaire
Number of subjects: 80
Study: 6992382

Group type: EXPERIMENTAL
Intervention: dimetikon 0.2 g 4 times daily, 3 days before examination
Number of subjects: 200
Study: 30683057

Group type: EXPERIMENTAL
Intervention: Titrated oxygen
Number of subjects: 35

Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 35
Study: 27577730

Group type: EXPERIMENTAL
Intervention: Union group (patients with successful union)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-union group (patients without successful union)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Union group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-union group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DSVA > 5 cm
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PI-LL > 30°
Number of subjects: 48
Study: 24529619

Group type: EXPERIMENTAL
Intervention: Recurrent headaches
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Migraines
Number of subjects: 872

Group type: COMPARATOR
Intervention: Silent cerebral infarction
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Medication for headache prophylaxis
Number of subjects: 872
Study: 22759328

Group type: EXPERIMENTAL
Intervention: 10-day concomitant therapy (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, metronidazole 400 mg three times a day, clarithromycin MR 1 g once daily)
Number of subjects: 110

Group type: COMPARATOR
Intervention: 5-day concomitant therapy (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, metronidazole 400 mg three times a day, clarithromycin MR 1 g once daily)
Number of subjects: 110
Study: 20451585

Group type: EXPERIMENTAL
Intervention: Dorsolateral prefrontal cortex stimulation at 2 or 4 V
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 5
Study: 17651267

Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dissection tonsillectomy with bipolar diathermy haemostasis
Number of subjects: 40
Study: 15520843

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 102
Study: 12008806

Group type: EXPERIMENTAL
Intervention: NiteWhite Excel 2Z
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rembrandt Xtra‐Comfort
Number of subjects: 18

Group type: COMPARATOR
Intervention: fx (Challenge Products)
Number of subjects: 18
Study: 10435819

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 30
Study: 7676685

Group type: EXPERIMENTAL
Intervention: 50 mg acetylsalicylic acid (Thrombo-ASS 50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin 100 mg (marketed preparation)
Number of subjects: 0
Study: 2151741

Group type: EXPERIMENTAL
Intervention: Corticosteroids and/or cytotoxic drugs
Number of subjects: 196

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 196
Study: 6119780

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine 200 mg twice daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg t.d.s. and 400 mg at night
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30878990

Group type: EXPERIMENTAL
Intervention: 4 weeks of plaster cast immobilisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6 weeks of plaster cast immobilisation
Number of subjects: 0
Study: 28030983

Group type: EXPERIMENTAL
Intervention: Perceived Benefits Scale
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Perceived Barriers Scale
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Physical Activity Enjoyment Scale
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Baseline MVPA and psychosocial benefits
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Physical benefits
Number of subjects: 1012
Study: 25134024

Group type: EXPERIMENTAL
Intervention: Postquit environmental risk factors (cigarette availability)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to contextual risk factors during the prequit period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cox regression survival analyses on time spent in high-risk contexts postquit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline risk factors (gender, nicotine dependence, depressive symptoms, living with a smoker)
Number of subjects: 0
Study: 24658473

Group type: EXPERIMENTAL
Intervention: 80 mg parecoxib per day (group I)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%, group II)
Number of subjects: 20
Study: 21068096

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (depomedrone)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Non-animal stabilised hyaluronic acid (durolane)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard care (no injection)
Number of subjects: 77
Study: 19339358

Group type: EXPERIMENTAL
Intervention: Citalopram (dosage not specified)
Number of subjects: 2855
Study: 17534686

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg intravenously every 2 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg intravenously every 2 weeks) plus low-dose interferon alfa-2b (1 MU/m2 subcutaneously daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-dose interferon alfa-2b (1 MU/m2 subcutaneously daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bevacizumab with or without low-dose interferon alfa-2b
Number of subjects: 32
Study: 16701925

Group type: EXPERIMENTAL
Intervention: 3000 pfu Towne CMV vaccine with adjuvant recombinant interleukin-12 (rhIL-12)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3000 pfu Towne CMV vaccine without adjuvant recombinant interleukin-12 (rhIL-12)
Number of subjects: 0
Study: 15131557

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 200
Study: 11016321

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 70
Study: 8795400

Group type: EXPERIMENTAL
Intervention: Pentosan polysulphate sodium (PPS) 200 mg three times daily for 6 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 1825503

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg t.i.d. for 5-6 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6336819

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (given intravenously on eight consecutive days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Supportive care alone (control group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (given subsequently to control patients)
Number of subjects: 42
Study: 31455871

Group type: EXPERIMENTAL
Intervention: High fat meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 16

Group type: COMPARATOR
Intervention: scAT (subcutaneous abdominal adipose tissue)
Number of subjects: 16
Study: 31827657

Group type: EXPERIMENTAL
Intervention: Preoperative PVB with PCIA (Group A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Postoperative PVB with PCIA (Group B)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination of preoperative and postoperative PVB (Group C)
Number of subjects: 44
Study: 28625369

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 36

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 36
Study: 25428694

Group type: EXPERIMENTAL
Intervention: Parent‐adolescent group‐administered (PA)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Self‐administered with telephone support (SA)
Number of subjects: 331

Group type: COMPARATOR
Intervention: No‐treatment control
Number of subjects: 331
Study: 24366288

Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg
Number of subjects: 199

Group type: COMPARATOR
Intervention: rabeprazole 10 mg
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg (CYP2C19 PM phenotype)
Number of subjects: 199

Group type: COMPARATOR
Intervention: rabeprazole 10 mg (CYP2C19 PM phenotype)
Number of subjects: 199
Study: 23078196

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment as usual control
Number of subjects: 61
Study: 19237631

Group type: EXPERIMENTAL
Intervention: Trials stopped early for positive results
Number of subjects: 27
Study: 17533782

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine ophthalmic emulsion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine cataract extraction
Number of subjects: 0
Study: 15206909

Group type: EXPERIMENTAL
Intervention: Apomorphine 2 mg (titrated up to 3 mg if necessary)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (titrated up to 100 mg if necessary)
Number of subjects: 40
Study: 11452249

Group type: EXPERIMENTAL
Intervention: Ibutamoren mesylate 0.8 mg/kg per day for 8 days (group III)
Number of subjects: 18
Study: 9554633

Group type: EXPERIMENTAL
Intervention: Electronic peak flowmeter (with a 3-month memory)
Number of subjects: 26
Study: 7802600

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (BDP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral prednisolone (PSL)
Number of subjects: 24
Study: 2839444

Group type: EXPERIMENTAL
Intervention: Post-operative thoracic radiation with systemic chemotherapy (cytoxan, adriamycin, and platinum) for 6 months
Number of subjects: 164

Group type: COMPARATOR
Intervention: Post-operative thoracic radiation without systemic chemotherapy
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Combined therapy group (radiation + chemotherapy)
Number of subjects: 164
Study: 31733608

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus memory support (CS + Memory Support; n = 22)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cognitive therapy as-usual (CT-as-usual; n = 20)
Number of subjects: 42
Study: 31185995

Group type: EXPERIMENTAL
Intervention: Structured personal diabetes care for 6 years
Number of subjects: 1381

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 1381

Group type: EXPERIMENTAL
Intervention: Structured personal diabetes care
Number of subjects: 1381
Study: 27559857

Group type: EXPERIMENTAL
Intervention: Resilience and Coping Intervention (RCI)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control
Number of subjects: 129
Study: 26353786

Group type: EXPERIMENTAL
Intervention: Collagen peptides (15 g/d)
Number of subjects: 53
Study: 23896763

Group type: EXPERIMENTAL
Intervention: 7-T MRI with bilateral transmit-receive coil and adiabatic inversion-based fat suppression (FS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 3-T MRI
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 7-T MRI
Number of subjects: 17
Study: 21338535

Group type: EXPERIMENTAL
Intervention: HDP meal (hydroxypropyl-distarch phosphate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Waxy maize starch meal
Number of subjects: 10
Study: 19549022

Group type: EXPERIMENTAL
Intervention: Decision support advising against nine potentially inappropriate medications
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no decision support)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Decision support
Number of subjects: 63
Study: 17634049

Group type: EXPERIMENTAL
Intervention: Xian-zhong injection
Number of subjects: 127

Group type: COMPARATOR
Intervention: Sodium Hyaluronate injection
Number of subjects: 127
Study: 15164445

Group type: EXPERIMENTAL
Intervention: Cytoreduction followed by hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 102
Study: 12583553

Group type: EXPERIMENTAL
Intervention: meropenem 500 mg i.v. t.i.d.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin 500 mg i.v. t.i.d.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: clarithromycin 500 mg + ceftriaxone 1 g i.v. b.i.d.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: clarithromycin 500 mg + amikacin 250 mg i.v. b.i.d.
Number of subjects: 204
Study: 10404804

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 5 mg
Number of subjects: 1202
Study: 8527541

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 177

Group type: COMPARATOR
Intervention: Tobramycin plus Clindamycin (T/C)
Number of subjects: 177
Study: 2316078

Group type: EXPERIMENTAL
Intervention: Cisplatin treatment without nephroprotection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin treatment with nephroprotective amino acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ionic contrast media during urography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ionic contrast media during urography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute pyelonephritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower urinary tract infections
Number of subjects: 0
Study: 6938012

Group type: EXPERIMENTAL
Intervention: estramustine phosphate (Estracyt)
Number of subjects: 212

Group type: COMPARATOR
Intervention: polyestradiol phosphate and ethinyl estradiol
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Previous cardiovascular disease
Number of subjects: 212
Study: 31888713

Group type: EXPERIMENTAL
Intervention: Bimin decoction (BMD)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Fluticasone nasal spray and loratadine tablets
Number of subjects: 108
Study: 27388441

Group type: EXPERIMENTAL
Intervention: 1-year intervention focusing on increasing physical activity (PA) and fruit and vegetable intake (FVI), decreasing screen media use (SMU) and soft drink consumption (SDC)
Number of subjects: 525
Study: 25531240

Group type: EXPERIMENTAL
Intervention: Algorithm-based care (administered by a dedicated research nurse)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Algorithm-based care
Number of subjects: 16
Study: 23408834

Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Premalignant and early stages of myeloma
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Advanced stages of myeloma
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: DNMT3A underexpression
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Hypomethylating agents
Number of subjects: 56
Study: 21220074

Group type: EXPERIMENTAL
Intervention: 15 mg oral hydrocortisone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19371934

Group type: EXPERIMENTAL
Intervention: Amlodipine plus terazosin (5 mg Amlodipine + 2 mg terazosin)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Terazosin (2 mg)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Amlodipine (5 mg)
Number of subjects: 355
Study: 17376205

Group type: EXPERIMENTAL
Intervention: Local heat therapy by radiofrequency (RF) at 50 degrees C for 30 s once weekly for 4 weeks
Number of subjects: 117

Group type: COMPARATOR
Intervention: Intralesional injection of meglumine antimoniate once weekly for 4 weeks
Number of subjects: 117
Study: 15456084

Group type: EXPERIMENTAL
Intervention: Reverset (RVT) 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Reverset (RVT) 10-200 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11432083

Group type: EXPERIMENTAL
Intervention: POLY-Nag (N-acetyl-D-glucosamine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0